MassHealth Drug Utilization Review (DUR) Program (800) 745-7318 (phone) (877) 208-7428 (fax)

DUR BOARD MEETING (REMOTE) Quarterly Meeting September 11, 2024

AGENDA

I. Welcome and Introductory Remarks

II. Pipeline Update

The Pipeline Update will provide a brief overview of clinical and regulatory updates regarding select pharmaceutical pipeline agents in late-stage development.

III. Annual Special Populations Update

This overview is a summary of the current structure of the Drug Utilization Review Special Populations Program. It summarizes clinical outcomes of the program over the past year.

IV. RSV—Quality Assurance Analysis and Seasonal Update

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.

V. Respiratory Agents, Inhaled—Quality Assurance Analysis

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.

VI. MHDL Update

MHDL Overview includes new additions, changes in prior authorization (PA) status, and related attachment updates to be implemented with a recent publication rollout.

VII. DUR Operational Update

DUR Operational Overview includes statistics associated with PA review, PA response, and Call Center metrics

VIII. MassHealth Update

MassHealth Update is a brief summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.

IX. Hypnotics—Quality Assurance Analysis (time permitting)

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.

X. Open Forum

Zoom link: https://umassmed.zoom.us/j/91737292307?pwd=bsN5fFik6xkupFPW6opj1zdHrEJqnx.1

The Massachusetts Commission for the Deaf and Hard of Hearing will assist with arrangements for a sign language interpreter. The Commission may be reached at 617-740-1600 (voice) and 617-740-1700 (TTY).

Next DUR Board (open meeting): December 11, 2024